Skip to main content Accessibility help
×
Home

The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries

  • C. G. ANASTASSOPOULOU (a1), G. KAFATOS (a2), A. NARDONE (a2), N. ANDREWS (a2), R. G. PEBODY (a2), J. MOSSONG (a3), I. DAVIDKIN (a4), D. GELB (a2), F. DE ORY (a5), W. THIERFELDER (a6), V. NEMECEK (a7), B. BRUZZONE (a8), D. BUTUR (a9), C. BARBARA (a10), Z. SOBOTOVÁ (a11), L. JONES (a12), A. GRISKEVICIUS (a13), L. M. HESKETH (a2), D. COHEN (a14), R. VRANCKX (a15), A. TSAKRIS (a16), E. MILLER (a2) and A. HATZAKIS (a1)...

Summary

The European Sero-Epidemiology Network 2 (ESEN2) aimed to compare serological results of vaccine-preventable diseases across Europe. To ensure direct inter-country comparability of hepatitis A virus antibody (anti-HAV) measurements, a standardization panel of 150 sera was developed by a designated reference laboratory and tested by participating national laboratories using assays of choice; each country's results were subsequently regressed against those of the reference laboratory. Quantitatively, the assays were generally highly correlated (R2>0·90). Nevertheless, qualitative comparisons indicated that results obtained with different assays may differ despite the usage of well-established international and local standards. To a great extent standardization successfully alleviated such differences. The generated standardization equations will be used to convert national serological results into common units to enable direct international comparisons of HAV seroprevalence data. The results of this study are expected to contribute to the evaluation and potential improvement of the currently employed immunization strategies for hepatitis in Europe.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Dr A. Hatzakis, Professor of Epidemiology and Preventive Medicine, National Retrovirus Reference Centre, Chief, Department of Hygiene and Epidemiology, University of Athens Medical School, 75 Mikras Asias Street, GR-115 27 Athens (Goudi), Greece. (Email: ahatzak@med.uoa.gr)

References

Hide All
1. Vento, S, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. New England Journal of Medicine 1998; 338: 286290.
2. Lednar, WM, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. American Journal of Epidemiology 1985; 122: 226233.
3. Forbes, A, Williams, R. Changing epidemiology and clinical aspects of hepatitis A. British Medical Bulletin 1990; 46: 303318.
4. Keeffe, EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? American Journal of Gastroenterology 1995; 90: 201205.
5. Franco, E, et al. Risk groups for hepatitis A virus infection. Vaccine 2003; 21: 22242233.
6. Steffen, R, Banos, A, deBernardis, C. Vaccination priorities. International Journal of Antimicrobial Agents 2003; 21: 175180.
7. Frosner, GG, et al. Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups. American Journal of Epidemiology 1979; 110: 6369.
8. Dienstag, JL, et al. Hepatitis A virus infection: new insights from seroepidemiologic studies. Journal of Infectious Diseases 1978; 137: 328340.
9. Szmuness, W, et al. The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. American Journal of Epidemiology 1977; 106: 392398.
10. Schenzle, D, Dietz, K, Frosner, GG. Antibody against hepatitis A in seven European countries. II. Statistical analysis of cross-sectional surveys. American Journal of Epidemiology 1979; 110: 7076.
11. Jacobsen, KH, Koopman, JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiology and Infection 2004; 132: 10051022.
12. Osborne, K, Weinberg, J, Miller, E. The European Sero-Epidemiology Network. Eurosurveillance 1997; 2: 2931.
13. Nardone, A, Miller, E. Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2). Eurosurveillance 2004; 9: 57.
14. Desquesnes, M. International and regional standardization of immunoenzyme tests: methods, concerns and limitations [in French]. Revue Scientifique et Technique de l'Office International des Epizooties 1997; 16: 809823.
15. Hesketh, L, et al. An evaluation of nine commercial EIA kits for the detection of measles specific IgG. Journal of Virological Methods 1997; 66: 5159.
16. Andrews, N, et al. The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiology and Infection 2000; 125: 127141.
17. Giammanco, A, et al. European Sero-Epidemiology Network: standardisation of the assay results for pertussis. Vaccine 2003; 22: 112120.
18. de Ory, F, et al. European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus. Journal of Clinical Virology 2006; 36: 111118.
19. von Hunolstein, C, et al. European sero-epidemiology network: standardisation of the results of diphtheria antitoxin assays. Vaccine 2000; 18: 32873296.
20. Tischer, A, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiology and Infection 2007; 135: 787797.
21. Kafatos, G, et al. The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virus. Journal of Viral Hepatitis 2007; 14: 260268.
22. Wiedmann, M, et al. Evaluation of three commercial assays for the detection of hepatitis a virus. European Journal of Clinical Microbiology and Infectious Diseases 2003; 22: 129130.
23. Shao, ZJ, et al. Detection of anti-HAV antibody with dot immunogold filtration assay. World Journal of Gastroenterology 2003; 9: 15081511.
24. Berger, R, Just, M, Althaus, B. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: the results are highly dependent on the antibody test system used. Journal of Virological Methods 1993; 43: 287297.
25. Coulepis, AG, et al. Detection of hepatitis A virus and antibody by solid-phase radioimmunoassay and enzyme-linked immunosorbent assay with monoclonal antibodies. Journal of Clinical Microbiology 1985; 22: 119124.
26. Hess, G, et al. Analysis of immunoassays to detect antibodies to hepatitis A virus (anti-HAV) and anti-HAV immunoglobulin M. Journal of Virological Methods 1995; 51: 221228.
27. Delem, AD. Comparison of modified HAVAB and ELISA for determination of vaccine-induced anti-HAV response. Biologicals 1992; 20: 289291.
28. Robbins, DJ, et al. Detection of total antibody against hepatitis A virus by an automated microparticle enzyme immunoassay. Journal of Virological Methods 1991; 32: 255263.
29. Safford, SE, Needleman, SB, Decker, RH. Radioimmunoassay for detection of antibody to hepatitis A virus. Results of clinical evaluation. American Journal of Clinical Pathology 1980; 74: 2531.
30. Drucker, J, et al. Serologic response in human hepatitis A: detection of antibody by radioimmunoassay and immune adherence hemagglutination. Journal of Medical Virology 1979; 4: 5158.
31. Sjogren, MH, et al. Immunogenicity of an inactivated hepatitis A vaccine. Annals of Internal Medicine 1991; 114: 470471.
32. Kafatos, G, Andrews, N, Nardone, A (on behalf of the ESEN2 project). Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 50225027.
33. Anastassopoulou, CG, et al. Epidemiological patterns of hepatitis A and B in Athens, Greece in 2001. 9th European Programme for Intervention Epidemiology Training (EPIET)/EPIET Alumni Network (EAN) Scientific Seminar, Minorca, Spain, 1416 October 2004. EU Designated surveillance networks/Abstract No. 5.
34. Lubin, JH, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environmental Health Perspectives 2004; 112: 16911696.

Keywords

The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries

  • C. G. ANASTASSOPOULOU (a1), G. KAFATOS (a2), A. NARDONE (a2), N. ANDREWS (a2), R. G. PEBODY (a2), J. MOSSONG (a3), I. DAVIDKIN (a4), D. GELB (a2), F. DE ORY (a5), W. THIERFELDER (a6), V. NEMECEK (a7), B. BRUZZONE (a8), D. BUTUR (a9), C. BARBARA (a10), Z. SOBOTOVÁ (a11), L. JONES (a12), A. GRISKEVICIUS (a13), L. M. HESKETH (a2), D. COHEN (a14), R. VRANCKX (a15), A. TSAKRIS (a16), E. MILLER (a2) and A. HATZAKIS (a1)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed